CASI Pharma Taps Athenex's Daniel Lang, MD as CFO
Portfolio Pulse from Benzinga Newsdesk
CASI Pharmaceuticals (NASDAQ:CASI) has appointed Dr. Daniel Lang as its new Chief Financial Officer and Senior Vice President, effective July 8th, 2024. Dr. Lang brings over 30 years of experience in the biotech sector, including roles as a physician scientist, investor, and executive.
July 08, 2024 | 11:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CASI Pharmaceuticals has appointed Dr. Daniel Lang as CFO and SVP, effective July 8, 2024. Dr. Lang's extensive experience in biotech and investment could positively impact CASI's strategic direction and financial management.
The appointment of Dr. Lang, with his extensive background in biotech and investment, is likely to be viewed positively by investors. His experience could enhance CASI's strategic and financial management, potentially leading to better performance and growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100